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To determine immunologic reactivity to Bacillus anthrax 
antigens, we conducted serologic testing of workers in a 
factory that performed scouring of wool and goat hair. Of 66 
workers, ≈10% had circulating antibodies or T lymphocytes 
that reacted with anthrax protective antigen. Individual im-
munity varied from undetectable to high. 
I
ndustrial anthrax, also known as woolsorter’s disease, 
was a serious threat in the 19th and early 20th centuries 
when the wool industry was flourishing. The causal agent, 
Bacillus anthracis, was brought into factories in sporulated 
form with the organic matter that was contaminating the 
animal  fibers.  The  pathogen  provoked  the  characteristic 
necrotic lesions on the skin of the wool workers (cutane-
ous anthrax), but it could also cause a respiratory disease 
through  airborne  transmission  (inhalational  anthrax).  In 
1950, 90% of those with the latter form died, although the 
proportion of deaths could be lowered to 50% with the 
aggressive therapy that was later used to treat the victims 
of the deliberate release of anthrax in the United States in 
2001 (1,2). 
Today, industrial processing of wool and goat hair has 
almost disappeared from Western industrialized countries. 
Cases of human anthrax have become rare in Europe (3,4), 
but they can sometimes result from contact with imported 
contaminated material (6,6). Apart from the 2001 attacks 
(7), the most recent human anthrax epidemic in the United 
States was reported in 1957 in a large goat hair–processing 
mill in Manchester, New Hampshire (1). In a recent study, 
we investigated the microbiologic flora of a Belgian fac-
tory (in operation since 1880) that processes and scours 
wool and goat hair from all over the world. Living anthrax 
spores were demonstrated in goat hair fibers, air dust, and 
unprocessed wastewater produced from goat hair scouring 
(8). No clinical case of anthrax was recorded among the 
employees of this company except for a possible cutaneous 
lesion, reported by a worker in 2002, the cause of which re-
mained unconfirmed. In the current study, we investigated 
the immunity of the factory workers. Since none of these 
workers had been vaccinated against anthrax, we assumed 
that  immunologic  reactivity  to  anthrax  antigens,  if  any, 
would very likely demonstrate exposure to B. anthracis.
The Study
Blood samples were obtained from 66 of the 67 factory 
workers, including the administrative employees. Serologic 
testing was carried out at 2 time points (December 2006 and 
December 2007) by using a commercial ELISA (Serion, 
Würzburg, Germany) based on plates coated with purified 
anthrax protective antigen (PA) (online Technical Appen-
dix, available from www.cdc.gov/EID/content/15/10/1637-
Techapp.xls). The first year, 3 workers had immunoglobu-
lin (Ig) G titers above the threshold recommended by the 
manufacturer for vaccine protection (>15 IU/mL), and ti-
ters for another worker were considered borderline (10–15 
IU/mL). All 4 workers had positive results by Western blot 
or dot blot analysis with pure recombinant anthrax PA and 
lethal factor (LF). One year later, 54 workers were sampled 
(2 were new employees). The second round of testing gave 
similar  results,  except  for  3  additional  borderline  cases 
which could also be confirmed by Western blot/dot blot 
analysis  (Table).  Lymphocyte  proliferation  assays  were 
performed concurrently by using fresh, heparinized, whole 
blood samples to evaluate the cell-mediated immunity of 
the  workers  (9).  This  technique  measures  the  ability  of 
lymphocytes placed in short-term tissue culture to undergo 
clonal proliferation when stimulated in vitro by a foreign 
antigen. Cell proliferation was determined by measuring 
the incorporation of 3H-thymidine into chromosomal DNA. 
The release of interferon-gamma (IFN-γ) in the course of 
lymphocyte stimulation was also measured to assess anti-
gen-specific, cell-mediated reactivity. The  antigens used 
here were pure recombinant PA and LF, along with posi-
tive control (concanavalin A) and negative control (phos-
phate buffer) stimulants. As shown in the Table, 2 cultures 
were positive in proliferation assays. Of these 2 cultures, 1 
reacted with PA and LF, and 1 reacted with PA only. When 
added together, PA and LF suppressed the proliferative ef-
fect of the individual antigens, consecutive to the probable 
cytotoxicity induced by the 2 assembled antigens (porin + 
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sults are shown in Figure 1. The lymphocyte cultures found 
to be responsive to pure anthrax antigens originated from 
workers who had little circulating anti-PA IgG (<15 IU/
mL), as tested by ELISA (Figure 2). However, their serum 
tested positive by Western blot analysis (Table). Moreover, 
supernatants of PA-stimulated lymphocyte cultures derived 
from the blood of these workers with positive results by 
determining counts per minute, were confirmed by IFN-γ 
release assay.
Conclusions
Although some progress made in improving the bio-
logic safety of the industrial processing of wool and goat 
hair (for example, systematic disinfection, air filtering, 
and protective gear for employees working in closed ar-
eas), this study shows that B. anthracis still poses a health 
risk to modern wool workers. Handling nondisinfected, 
raw animal fibers from areas where anthrax is endemic, 
such  as  the  southern  Caucasus  region  and  the  Middle 
East, has been and remains an at-risk activity. The pres-
ence  of  circulating  antibodies  and  T  lymphocytes  that 
react  with  antigens  expressed  only  by  vegetative  cells 
of B. anthracis in unvaccinated wool workers confirms 
several  previous  findings.  First,  these  findings  support 
the conclusions that anthrax spores are able to germinate 
into vegetative cells at the sites of exposure (skin, mu-
cosa, respiratory tract) and cause asymptomatic infection 
(10,11). Second, the extent to which the human immune 
system responds to exposure to anthrax spores from the 
surrounding environment as well as the nature of this re-
sponse varies tremendously from person to person. This 
conclusion was well exemplified by the situations of 2 
workers. Results from 1 worker (T29) displayed a high 
IgG titer (>100 U/mL) but little or no cell-mediated re-
activity. Results from the other worker (T2) showed sig-
nificant lymphocyte reactivity (3H-Thymidin counts >700 
counts per minute, which corresponds to a proliferative 
index of 6, p>0.01), but a low IgG titer (Figure 2), which 
reflects reciprocal T- and B-cell responses. None of the 
persons whose samples tested positive by ELISA reported 
a past episode of anthrax (according to face-to-face inter-
views conducted when blood was sampled). Hence, their 
seroconversion most likely resulted from asymptomatic 
B. anthracis infection. One worker reported having had a 
skin lesion possibly compatible with cutaneous anthrax 4 
years before the study. That worker’s samples tested posi-
tive by lymphocyte proliferation assay, Western blot, and 
dot blot, but not by anti-PA ELISA.
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Table. Number of workers showing immunoreactivity against Bacillus anthracis antigens, as assayed by 3 different methods* 
Anti-PA ELISA†  Western blot/dot blot‡  LT proliferation§ 
Status  Year 1  Year 2    Year 1  Year 2  Ag = PA  Ag = LF  Ag = PA + LF Ag = conA 
Negative  62  48    –  –  52  53  54  13 
Positive  3  2    4  6  2¶  1¶#  0  41 
Borderline  1  4    –  –  0  0  0  0 
*PA, protective antigen; LT, lymphocyte; Ag, antigen; LF, lethal factor; conA, concanavalin A. 
†Performed on serum samples according to the manufacturer’s instructions and thresholds (Serion, Würzburg, Germany). Note: 1 worker tested positive 
at year 1 was not enrolled at year 2, and 3 workers tested negative at year 1 seroconverted to borderline at year 2. 
‡Conducted only on serum samples found positive or borderline by anti-PA ELISA together with negative controls (n = 25). Dot blots were spotted with 
1,000, 100, 10, and 1 ng of each purified PA and LF Ag purchased from Quadratech Ltd. (Epson, UK). Western blot antigens consisted in supernatant 
proteins derived from the culture of a reference B. anthracis strain. 
§Assayed on blood samples from year 2 as described earlier (9) by using a proliferative index threshold set to 3× the index of a negative control stimulant 
(phosphate buffer). Stimulating Ag was used at a final concentration of 4 mg/mL (PA, LF, conA). ConA was used as positive control stimulant and was 
purchased from Sigma (St. Louis, MO, USA). Lymphocyte cultures found activatable by PA were confirmed by quantifying IFN-Ȗ release by ELISA, 
according to the manufacturer’s instructions (Pierce, Rockford, IL, USA) 
¶Serum samples from these workers tested positive by both Western blot and dot blot analysis. 
#This culture was also stimulated by PA. 
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Figure  1.  Representative  examples  of  lymphocyte  proliferation 
results.  Proliferation  was  assayed  by  measuring  3H-Thymidin 
incorporation  (counts  per  minute  [cpm])  of  culture  lymphocytes 
stimulated with different antigens and by determining the respective 
proliferative  Indexes.  The  latter  were  calculated  by  dividing  the 
cpm induced by a given antigen by the cpm induced by a negative 
control  antigen  (phosphate-buffered  saline  (PBS),  white  boxes). 
The proliferative index is a parameter that reflects the reactivity 
of a lymphocyte culture toward a given antigen. It is indicative of 
the cellular immunity of a person toward this antigen. The antigens 
used in this experiment are listed in the Table. The figure shows 
3 representative culture profiles that react either with protective 
antigen (PA) and lethal factor (LF) (1 sample, T2), with PA only 
(1 sample, T9), or with none of them (41 samples, exemplified by 
T56). Each value is the mean of 3 independent experiments and is 
shown with the standard deviation (error bar).Unvaccinated Workers and Anthrax, Belgium
Notably, samples from many workers from the same 
factory, who had been exposed to goat hair for years in 
similar conditions, did not display positive serologic results 
when tested by ELISA. During our study, however, we no-
ticed that serum samples from 3 workers had seroconverted 
from negative to partially protective (borderline) IgG titers 
at some point between the 2 blood samplings as determined 
by anti-PA ELISA. Given the long history of these workers 
at the company, the apparent lack of anti-PA antibodies at 
the first blood sampling may have been misestimated due 
to the high threshold defined for seropositivity by the com-
mercial ELISA used in the study. This commercial kit is in-
deed primarily aimed at evaluating the efficacy of anthrax 
vaccination rather than at detecting antibody responses af-
ter exposure to subinfectious doses of anthrax spores (12). 
Accordingly, we noticed that of the 3 workers who sero-
converted, 2 tested positive by Western blot, and 1 tested 
positive by dot blot when tested retrospectively at year 1. 
Blotting techniques seem thus more sensitive than the pres-
ently used ELISA seropositivity threshold for detecting low 
anti-PA antibody titers. The low sensitivity of the method 
used in this work to assess cell-mediated immunity (whole 
blood proliferation assay) may have also underestimated 
the actual number of workers who exhibited cell-mediated 
immunity against B. anthracis, and the results should be 
regarded as indicative rather than representative.
PA-based  anthrax  vaccines  are  available  to  protect 
professionally  exposed  people,  such  as  the  US  anthrax 
vaccine adsorbed or the UK anthrax vaccine. These vac-
cines are efficient and elicit humoral responses that protect 
the  vaccinees  against  toxin-associated  death  (13).  They 
do require long clinical protocols and yearly boosters (14) 
and are not officially licensed in European Union member 
states (except the United Kingdom). According to some 
authors, these vaccines might not protect wool-workers ef-
ficiently against subclinical infection, spore germination, 
or bacteremia (13,15). Anthrax vaccines that confer long-
term immunity of both the humoral and cellular type are 
not yet available for the general public. Vaccines with such 
characteristics would be highly desirable to better protect 
persons who work with animal products that are possibly 
contaminated with anthrax spores.
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  Figure  2.  Graph  showing  anti–protective  antigen  (PA) 
immunoglobulin G (IgG) titers plotted against  3H-thymidin counts 
per minute (cpm) derived from PA-stimulated blood cell cultures 
conducted in year 2. The vertical lines define the ELISA borderline 
and upper thresholds (10 IU/mL and 15 IU/mL, respectively), which 
were defined as PA titers by the ELISA kit manufacturer, i.e., titers 
supposed to confer protection after vaccination. Samples testing 
below the borderline threshold are considered negative. T29 and 
T2 refer to workers whose samples had a remarkably high antibody 
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